Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

The vaccine demonstrated overall efficacy of 82.5% in adults aged 60 years and older

- PMLiVE

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

The study showed significant improvements in red blood cell transfusion independence

- PMLiVE

Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial

BI 1015550 reduced the rate of lung function decline in patients with IPF in a phase 2 trial

Internal Brand Planning Sessions on the Impetus InSite Platform®

A Customer Story

Impetus Digital

- PMLiVE

Cross-functional alignment

By Professor Brian D Smith

- PMLiVE

GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention

Cabotegravir offers up to two months of protection from a single injection

- PMLiVE

Act-Accelerator outlines plans for longterm COVID-19 control

Its plan highlights key priorities as countries transition to manage the public health issue

- PMLiVE

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The submission includes positive data from the pivotal phase 2b and four open-label studies

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

NHS England hits ten million in autumn COVID-19 booster campaign

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

Personalized Oncology: Calling for a New Kind of Partnership:

In the 1990s, biomarkers were the future of personalized medicine and a “lab on a chip” was the holy grail of understanding patient health. As much as past predictions of...

Inizio

- PMLiVE

Are smart deals a clever solution to UK market access?

By James Lister, Ewa Kania and Janica Auluck

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links